Study of IMM 101 in Combination With Standard of Care in Patients With Metastatic or Unresectable Cancer
Status:
Terminated
Trial end date:
2017-08-30
Target enrollment:
Participant gender:
Summary
During this open label study patients will receive IMM-101 in conjunction with a recognised
standard of care for metastatic or unresectable cancer for the patient's specific tumour
type.
The primary objective of the study is to provide safety data for IMM-101 in combination with
a number of selected standard of care regimens.